Vir Biotechnology, Inc. (VIR) Wednesday announced encouraging results from Phase 1 studies of its two drug candidates VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors. The company's shares were more than 38 percent up in pre-market.
VIR-5818 is being evaluated in Phase 1 trial to study its safety and pharmacokinetics alone, and in combination with pembrolizumab, in participants with a variety of HER2-expressing cancers, including breast and colorectal cancer (CRC). Data from the study showed that 50 percent of participants treated with VIR-5818 experienced tumor shrinkage across multiple HER2-positive tumor types.
VIR-5500 is being evaluated in a Phase 1 trial designed to assess its safety, pharmacokinetics, and efficacy in participants with metastatic castration-resistant prostate cancer (mCRPC). Data from the study showed prostate-specific antigen (PSA) reductions in all the participants.
Vir Biotechnology stock had closed at $7.89, down 0.75 percent on Tuesday. It has traded in the range of $6.56 - $13.09 in the last 1 year.
For comments and feedback: editorial@rttnews.com